Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
2.
Am J Prev Med ; 20(3 Suppl): 62-72, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11306234

ABSTRACT

CONTEXT: Bacterial vaginosis (BV) is a strong independent risk factor for adverse pregnancy outcomes. BV is found in 9% to 23% of pregnant women. Symptoms include vaginal discharge, pruritus, or malodor, but often women with BV are asymptomatic. OBJECTIVES: To determine whether screening and treating pregnant women for BV reduces adverse pregnancy outcomes, as part of an assessment for the U.S. Preventive Services Task Force. DATA SOURCES: Randomized clinical trials of BV treatment in pregnancy that measured pregnancy outcomes were identified from multiple searches in MEDLINE from 1966 to 1999, the Cochrane Controlled Trials Register and Library, and national experts. STUDY SELECTION: All randomized controlled trials of BV treatment in pregnancy that specifically measured pregnancy outcomes. DATA EXTRACTION: The following information was abstracted: study design and blinding, diagnostic methods, antibiotic interventions, timing of antibiotic treatment in pregnancy, criteria for treatment, comorbidities, demographic details, risk factors for preterm delivery such as previous preterm delivery, compliance, rates of spontaneous and total preterm delivery less than 37 weeks and less than 34 weeks, preterm premature rupture of membranes, low birth weight less than 2500 grams, spontaneous abortion, postpartum endometritis, and neonatal sepsis. For each study, we measured the effect of treatment by calculating the difference in the rate of a given pregnancy outcome in the control group minus the treatment group (the absolute risk reduction [ARR]). A stepwise procedure based on the profile likelihood was applied to assess heterogeneity, to pool studies when appropriate, and to calculate the mean and 90% confidence intervals (CIs) for the effect of treatment. DATA SYNTHESIS: Seven randomized controlled trials met inclusion criteria for the meta-analysis. We found no benefit to BV treatment in average-risk women for any pregnancy outcome. Results of studies of high-risk populations, women with previous preterm delivery, were statistically heterogeneous. They clustered into two groups; one showed no benefit (ARR=-0.08, 90% CI=-0.19 to 0.04), whereas the three homogeneous studies showed potential benefit of BV treatment (pooled ARR=0.22; 90% CI=0.13 to 0.31) for preterm delivery before 37 weeks. Four high-risk studies reported results for preterm delivery less than 34 weeks. The pooled estimate showed no benefit (ARR=0.04; 90% CI=-0.02 to 0.09), but variation was noted among individual studies. Two trials of high-risk women found an increase in preterm delivery less than 34 weeks in women who did not have BV but received BV treatment. Comparisons of patient populations, treatment regimens, and study designs did not explain the heterogeneity among studies. CONCLUSIONS: We found no benefit to routine BV screening and treatment. A subgroup of high-risk women may benefit from BV screening and treatment; however, there may be a subgroup for whom BV treatment could increase the occurrence of preterm delivery.


Subject(s)
Mass Screening , Pregnancy Complications, Infectious/prevention & control , Prenatal Diagnosis , Vaginosis, Bacterial/prevention & control , Female , Humans , Infant, Newborn , Obstetric Labor, Premature/prevention & control , Pregnancy , Pregnancy Outcome , Randomized Controlled Trials as Topic , Risk
3.
Cancer Genet Cytogenet ; 122(2): 101-9, 2000 Oct 15.
Article in English | MEDLINE | ID: mdl-11106819

ABSTRACT

We report the cytogenetic abnormalities from a series of 206 primary malignant melanoma specimens referred to a single institution. A total of 169 out of 206 unique cases had chromosome breakpoints. A previously described statistical method was used to detect nonrandom distribution of chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints (indicating that the observed number of breaks significantly exceeded the expected number of breaks) was detected in 28 regions, suggesting a hierarchy of genetic abnormalities in melanoma. Clinical variables and tumor characteristics were analyzed for associations with the presence of any nonrandom chromosome breakpoints; with individual, nonrandomly involved chromosome regions; and with paired, nonrandomly involved chromosome regions. No nonrandomly involved chromosome regions or pairs of regions appeared to significantly affect survival. These results identify recurring, nonrandom chromosome abnormalities in malignant melanoma. These results suggest that recurring, nonrandom chromosome alterations play a key role in the etiology and/or progression of malignant melanoma and identify targets within the genome for molecular genetic studies.


Subject(s)
Chromosome Aberrations , Chromosome Disorders , Melanoma/genetics , DNA, Neoplasm/genetics , Female , Humans , Karyotyping , Male , Melanoma/pathology , Middle Aged , Ploidies , Survival Analysis
4.
Diabetes Res Clin Pract ; 50 Suppl 3: S15-46, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11080561

ABSTRACT

The attributes of Release 3.0 of the user friendly version (UFV) of the global diabetes model (GDM) are described and documented in detail. The GDM is a continuous, stochastic microsimulation model of type 2 diabetes. Suitable for predicting the medical futures of both individuals with diabetes and representative diabetic populations, the GDM predicts medical events (complications of diabetes), survival, utilities, and medical care costs. Incidence rate functions for microvascular and macrovascular complications are based on a combination of published studies and analyses of data describing diabetic members of Kaiser Permanente Northwest Region, a non-profit group-model health maintenance organization. Active risk factors include average blood glucose (HbAlc), systolic blood pressure (SBP), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides, smoking status, and use of prophylactic aspirin. Events predicted include diabetic eye disease, diabetic nephropathy, peripheral neuropathy amputation, myocardial infarction, stroke, peripheral artery disease, congestive heart failure, coronary artery surgery, coronary angioplasty, and death.


Subject(s)
Computer Simulation , Diabetes Mellitus, Type 2/physiopathology , Diabetes Mellitus, Type 2/therapy , Models, Statistical , Software , Age Factors , Databases as Topic , Diabetes Mellitus, Type 2/complications , Female , Humans , Male , Prognosis , Sex Factors , Stochastic Processes , Treatment Outcome
5.
Health Educ Behav ; 27(2): 232-40, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10768804

ABSTRACT

Peer education in the Arizona 5-a-Day project achieved lasting improvements in fruit and vegetable intake among multicultural employees. Measures monitored implementation of peer education from peer educators' logs, the program's reach from employee surveys, and employees' use in terms of employees' dietary change. Peer educators logged 9,182 coworker contacts. Contacts averaged 10.9 minutes, according to coworkers. Coworkers read an average of 4.7 booklets and 2.23 newsletters. Many employees talked with peer educators (59%) and read materials (54%) after the program finished. Employee reports of peer educator contact were positively associated with fruit and vegetable intake. Peereducation was implemented as intended and reached many coworkers. It continued after program completion, reached into coworkers' families, and was used by employees to improve intake. This method can be used with employees who rely on informal sources and whose work presents barriers to wellness activities.


Subject(s)
Diet , Health Promotion/methods , Nutritional Sciences/education , Occupational Health Services/organization & administration , Peer Group , Public Sector , Adult , Arizona , Female , Fruit , Humans , Male , Program Evaluation/methods
6.
Cancer Epidemiol Biomarkers Prev ; 9(12): 1281-6, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11142412

ABSTRACT

Alpha-2-(Difluoromethyl)-dl-ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, has been shown to suppress skin carcinogenesis in murine models after oral or topical administration. We designed a randomized, placebo-controlled study using a topical hydrophilic ointment formulation with or without 10% (w/w) DFMO. Forty-eight participants with moderate-severe actinic keratoses (AKs) on their forearms (i.e., at least 10 well-circumscribed lesions on the lateral surface) completed a 1-month run-in on placebo ointment. Before randomization, all lateral forearm AKs were circled, counted, photographed, and skin biopsies were obtained for DFMO and polyamine levels. Then participants were randomized to receive DFMO ointment on the right versus the left forearm and placebo hydrophilic ointment on the contralateral forearm twice daily for 6 months. DFMO was not detected in the blood of any subject, and there were no systemic toxicities. None of a subsample of 17 placebo forearms had measurable concentrations of DFMO, whereas 13 of the corresponding DFMO-treated forearms had high DFMO skin levels. As compared with placebo, the 6-month DFMO treatment caused a 23.5% reduction in the number of AKs (P = 0.001) as well as significant suppression of AK biopsy spermidine levels (26%; P = 0.04). Seven of the 48 (14.6%) participants experienced severe (2; 4.2%) or moderate (5; 10.4%) inflammatory reactions on their DFMO-treated arms which required dosing modification. Topical DFMO for 6 months can reduce the number of AK lesions and skin spermidine concentrations in high-risk participants and deserves additional study as a skin cancer chemopreventive agent.


Subject(s)
Antineoplastic Agents/therapeutic use , Eflornithine/therapeutic use , Enzyme Inhibitors/therapeutic use , Keratosis/prevention & control , Photosensitivity Disorders/prevention & control , Aged , Female , Humans , Keratosis/etiology , Male , Ointments , Photosensitivity Disorders/etiology
7.
J Natl Cancer Inst ; 91(17): 1491-500, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10469751

ABSTRACT

BACKGROUND: The National Cancer Institute recommends that Americans eat at least five daily servings of fruits and vegetables. National strategies to increase consumption may not reach minority and lower socioeconomic populations. In a randomized trial, peer education was tested for effectiveness at increasing fruit and vegetable intake among lower socioeconomic, multicultural labor and trades employees. METHODS: Employees (n = 2091) completed a baseline survey and received an 18-month intervention program through standard communication channels (e.g., workplace mail, cafeteria promotions, and speakers). Ninety-three social networks (cliques) of employees were identified, which were pair matched on intake. At an interim survey (during months 8 and 9), 11 cliques no longer existed and 41 matched pairs of cliques containing 905 employees remained, with one clique per pair being randomly assigned to the peer education intervention. Employees who were central in the communication flow of the peer intervention cliques served as peer educators during the last 9 months of the intervention program. Fruit and vegetable intake was measured with 24-hour intake recall and with food-frequency questions in baseline, outcome (i.e., at 18 months), and 6-month follow-up surveys. All P values are two-sided. RESULTS: By use of multiple regression, statistically significant overall effects of the peer education program were seen in the intake recall (increase of 0.77 total daily servings; P<.0001) and the food-frequency (increase of 0.46 total daily servings; P =.002) questions at the outcome survey. The effect on the total number of servings persisted at the 6-month follow-up survey when measured by the intake recall (increase of 0.41 total daily servings; P =.034) but not the food-frequency (decrease of 0.04 total daily servings; P =.743) questions. CONCLUSIONS: Peer education appears to be an effective means of achieving an increase in fruit and vegetable intake among lower socioeconomic, multicultural adult employees.


Subject(s)
Feeding Behavior , Fruit , Health Behavior , Health Education , Social Support , Vegetables , Workplace , Adult , Diet Surveys , Female , Health Education/methods , Health Knowledge, Attitudes, Practice , Health Promotion , Humans , Male , Middle Aged , Regression Analysis
8.
J Am Diet Assoc ; 99(8 Suppl): S96-104, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10450301

ABSTRACT

The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-Sodium) is a multicenter, randomized trial comparing the effects of 3 levels of sodium intake and 2 dietary patterns on blood pressure among adults with higher than optimal blood pressure or with stage 1 hypertension (120-159/80-95 mm Hg). The 2 dietary patterns are a control diet typical of what many Americans eat, and the DASH diet, which, by comparison, emphasizes fruits, vegetables, and low-fat dairy foods, includes whole grains, poultry, fish, and nuts, and is reduced in fats, red meat, sweets, and sugar-containing beverages. The 3 sodium levels are defined as higher (typical of current US consumption), intermediate (reflecting the upper limit of current US recommendations), and lower (reflecting potentially optimal levels). Participants are randomly assigned to 1 of the 2 dietary patterns using a parallel group design and are fed each of the 3 sodium levels using a randomized crossover design. The study provides participants with all of their food during a 2-week run-in feeding period and three 30-day intervention feeding periods. Participants attend the clinic for 1 meal per day, 5 days per week, and take home food for other meals. Weight is monitored and individual energy intake adjusted to maintain baseline weight. The primary outcome is systolic blood pressure measured at the end of each intervention feeding period. Systolic blood pressure is compared across the 3 sodium levels within each diet and across the 2 diets within each sodium level. If effects previously observed in clinical trials are additive, sodium reduction and the DASH diet together may lower blood pressure to an extent not as yet demonstrated for nonpharmacologic treatment. The DASH-Sodium results will have important implications for the prevention and treatment of high blood pressure.


Subject(s)
Blood Pressure , Diet , Hypertension/diet therapy , Randomized Controlled Trials as Topic , Research Design , Sodium, Dietary/administration & dosage , Adult , Humans , Multicenter Studies as Topic
9.
Genes Chromosomes Cancer ; 25(3): 290-300, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10379876

ABSTRACT

Cytogenetics provides important insights into the molecular pathogenesis of human cancers. Although extensive data exist on recurring cytogenetic abnormalities in hematologic cancers, data on individual solid tumor types remain limited. Previous studies of ovarian carcinoma indicated the presence of multiple, complex clonal chromosome abnormalities. Cytogenetics remains one of a few techniques capable of detecting these multiple, simultaneously occurring genetic abnormalities. We describe cytogenetic abnormalities from a series of 244 primary ovarian cancer specimens referred to a single institution. A total of 201/244 cases had fully characterized clonal chromosome abnormalities, of which 134 showed clonal chromosome breakpoints. We used a novel statistical technique to detect nonrandom chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints was detected at regions 1p1*, 1q1*, 1p2*, 1q2*, 1p3*, 1q3, 3p1*, 1q4*, 6q1*, 6p2, 6q2, 7p1*, 7q1, 7p2*, 11p1*, 11q1, 11q2*, 12p1, 12q2*, 13p1, and 19q1. Simultaneous occurrence of multiple abnormalities was common. However, 120/134 cases had breakpoints at one or more of 13 commonly involved regions (*), suggesting a hierarchy of genetic abnormalities. Among clinical and tumor variables that predict patient survival, tumor grade was significantly associated with the presence of chromosome breakpoints. In additional studies, we show that nonrandom chromosome abnormalities are associated with impaired survival in ovarian cancer and that specific, nonrandomly involved chromosome regions retain significant effects on survival when analyses are controlled for important clinical variables. Additional specific chromosome abnormalities in this series are described, including chromosome gains and losses in near-diploid cases and homogeneously staining regions. These results suggest that recurring, nonrandom chromosome abnormalities are important in the pathogenesis and/or progression of ovarian cancers, and target areas of the genome for molecular genetic studies.


Subject(s)
Adenocarcinoma/genetics , Chromosome Aberrations/genetics , Ovarian Neoplasms/genetics , Adenocarcinoma/mortality , Adult , Aged , Aged, 80 and over , Chromosome Aberrations/mortality , Chromosome Breakage , Chromosome Disorders , Female , Follow-Up Studies , Gene Amplification , Humans , Karyotyping , Middle Aged , Ovarian Neoplasms/mortality , Survival Rate , Translocation, Genetic
10.
Genes Chromosomes Cancer ; 25(1): 46-52, 1999 May.
Article in English | MEDLINE | ID: mdl-10221339

ABSTRACT

In a large series of ovarian carcinomas from 244 patients, 134 cases had chromosome rearrangements. We showed before that the pattern of chromosome breakpoints involved 21 separate chromosome regions nonrandomly and, in 90% of cases with breaks, the breakpoints occurred within 13 commonly involved regions. Log-rank and proportional hazards regression analyses showed that the aggregate presence of a chromosome breakpoint in any of 21 nonrandomly involved regions and breaks in 9 distinct regions (1p1, 1q2, 1p3, 3p1, 6p2, 11p1, 11q1, 12q2, and 13p1) were associated with reduced patient survival. Breakpoints in other areas of the genome, including other nonrandomly involved regions, were not associated with decreased survival. Because many cases had breakpoints in more than one nonrandomly involved region, proportional hazards regression was also used to analyze for effects of each nonrandomly involved region, controlling for effects of other regions. With this approach, only breakpoints within 1p1 and 3p1 retained independent, deleterious effects on survival. Similarly, when nonrandomly involved regions were entered into a proportional hazards model containing clinical variables associated with altered patient survival (tumor grade, tumor stage, and residual disease > 1 cm after resection), only 1p1 (P = 0.007) and 3p1 (P = 0.04) were associated with independent, negative effects on survival. These studies demonstrate that chromosome breakpoints within specific, nonrandomly involved chromosome regions are associated with impaired survival in ovarian cancers. Regions 1p1 and 3p1 are identified as areas of particular significance and are appropriate targets for analytical techniques such as SAGE and microarray analysis.


Subject(s)
Adenocarcinoma/genetics , Chromosome Aberrations/genetics , Ovarian Neoplasms/genetics , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Chromosome Aberrations/pathology , Chromosome Breakage/immunology , Chromosome Disorders , Female , Humans , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , Proportional Hazards Models
11.
BMJ ; 318(7176): 127-8, 1999 Jan 09.
Article in English | MEDLINE | ID: mdl-9880302
12.
Cancer Epidemiol Biomarkers Prev ; 7(9): 813-6, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9752991

ABSTRACT

The Wheat Bran Fiber (WBF) trial is a Phase III clinical trial designed to assess the effect of a WBF intervention for 3 years on the recurrence of adenomatous polyps. Men and women, 40-80 years of age, who had removal of one or more colorectal adenoma(s) 3 mm or larger within 3 months prior to study entry were recruited from three sites in the Phoenix metropolitan area. After meeting eligibility criteria, 1509 individuals entered a 6-week run-in period, consisting of a low WBF (2 g/day) intervention. Participants (n = 1429) successfully completed this phase and were randomized to a high (13.5 g/day) or low (2 g/day) WBF intervention. Various data and specimens were collected at baseline and throughout the intervention phase, which included dietary intake, physical activity, other risk factor information, blood specimens, rectal biopsies, and polyp tissues. The study design called for a colonoscopy at approximately 1 year after the qualifying colonoscopy; thus, the period between the first year and the final colonoscopy will be used to assess the effect of the intervention, which is expected to be completed in the latter part of 1998.


Subject(s)
Adenomatous Polyps/diet therapy , Dietary Fiber/therapeutic use , Adenomatous Polyps/prevention & control , Adult , Aged , Aged, 80 and over , Colonoscopy , Double-Blind Method , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Patient Selection , Prospective Studies , Protective Agents/therapeutic use , Research Design
13.
Stat Med ; 16(16): 1845-57, 1997 Aug 30.
Article in English | MEDLINE | ID: mdl-9280037

ABSTRACT

Adenomatous polyps are considered as the dominant precursor lesion of colorectal cancer. A phase III colorectal cancer prevention trial, conducted by the Arizona Cancer Center, concerns the ability of wheat bran fibre supplement to reduce the recurrence of adenomatous polyps. All participants in the study are to have had colorectal polyps detected and removed during a baseline (qualifying) colonoscopy within three months prior to enrolment. In this paper, our interest focuses on occurrence of adenomatous polyps at the baseline colonoscopy. We use a truncated Poisson model to fit these types of data. We develop a regression model to assess the effects of explanatory factors on the positive counting variable. We fit truncated Poisson parameters by a log-linear regression model and estimate regression parameters by the maximum likelihood procedure. Finally, we apply it to the baseline colonoscopy data from the Wheat Bran Fiber study.


Subject(s)
Adenomatous Polyps/diet therapy , Colorectal Neoplasms/diet therapy , Dietary Fiber/therapeutic use , Linear Models , Poisson Distribution , Adult , Aged , Aged, 80 and over , Clinical Trials, Phase III as Topic/methods , Colonoscopy , Female , Food, Fortified , Humans , Likelihood Functions , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control
14.
Cancer Epidemiol Biomarkers Prev ; 6(8): 583-7, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9264270

ABSTRACT

Nonmelanoma skin cancer, including both squamous cell carcinoma and basal cell carcinoma, is a significant and increasing health problem in the United States. The precursor lesion of cutaneous squamous cell carcinoma, actinic keratosis (AK), is a major risk factor for nonmelanoma skin cancer, and it is also a marker of long-term sun exposure. AKs themselves can serve as biomarkers in chemopreventive studies, but in addition, they may contain phenotypic and genetic alterations that are related to the process of UV-induced skin carcinogenesis. One of these alterations, the tumor suppressor gene p53, is altered early in UV-induced skin carcinogenesis in humans. p53 protein expression was measured by immunohistochemistry in biopsies from AKs, tissue immediately adjacent to AKs (AK-adjacent), normal-appearing upper medial arm skin, and non-sun-exposed skin from 19 subjects. There was a significant difference and a progressively increasing mean p53 labeling index in total epidermis (basal and suprabasal layers) between upper medial arm skin (0.9 +/- 1.8%) and AK-adjacent (12.1 +/- 14.4%; P = 0.0004) and between AK (27.7 +/- 21.3%) and AK-adjacent skin (P = 0.04), whereas upper medial arm skin was marginally different from non-sun-exposed skin (0.1 +/- 0.2; P = 0.05). This pattern of p53 expression was also seen when epidermis was separated into basal and suprabasal layers. We conclude that epidermal p53 protein expression is associated with histological evidence of chronic sun damage.


Subject(s)
Neoplasms, Radiation-Induced/genetics , Precancerous Conditions/genetics , Skin Neoplasms/genetics , Tumor Suppressor Protein p53/genetics , Aged , Aged, 80 and over , Biopsy , Carcinoma, Basal Cell/genetics , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged , Neoplasms, Radiation-Induced/pathology , Precancerous Conditions/pathology , Risk Factors , Skin/pathology , Skin Neoplasms/pathology , Sunlight/adverse effects
15.
In Vivo ; 11(3): 275-9, 1997.
Article in English | MEDLINE | ID: mdl-9239524

ABSTRACT

In a cancer chemoprevention trial, it is vitally important to use a dose that will limit intolerable side-effects. Unlike the situation with cancer drug treatment, the side-effects are relatively moderate, only rather low levels will be permitted, and the time to development of intolerability may be long and variable. These characteristics all argue in favor of a fixed-sample size, and a fixed-dose design. Here we give a very general procedure for selecting an acceptable dose for subsequent testing based on such a design. We also show how a simple program can display the characteristics of various designs graphically, permitting a common-sense selection.


Subject(s)
Chemoprevention , Clinical Trials, Phase II as Topic/methods , Models, Theoretical , Dose-Response Relationship, Drug , Humans
16.
Cancer Epidemiol Biomarkers Prev ; 6(5): 347-54, 1997 May.
Article in English | MEDLINE | ID: mdl-9149895

ABSTRACT

Cancer prevention clinical trials use food frequency questionnaires (FFQs) to assist in eligibility screening. FFQ reliability and validity studies are available, but these studies do not evaluate FFQs as screening tools. The Wheat Bran Fiber Trial of the University of Arizona used a FFQ as an eligibility screen with the goal of screening out subjects whose true daily calcium intake was less than 500 mg per day (for safety) and whose true dietary fiber intake was greater than 30 g per day (for safety and trial efficiency). Subjects ineligible by FFQ were interviewed for final dietary eligibility determinations. A study was undertaken within the Wheat Bran Fiber Trial to evaluate the sensitivity, specificity, positive predictive value, and negative predictive value (NPV) of the FFQ used in this context. Four-day food records were collected on 183 potential participants before entry into the study. Using the 4-day averages as the "true" value, sensitivity, specificity, positive predictive value, and NPV were calculated for men and women separately under two screening conditions: using the target calcium and dietary fiber values and using "revised" values identified in interim analysis within the study. NPV was acceptable in all analyses. Sensitivity for low calcium intake was inadequate under the original criteria (0.33 for men and 0.09 for women) but acceptable under the revised criteria (0.80 for men and 0.81 for women). With the revised criteria, specificity declined, resulting in heavy screening burdens deemed worthwhile for the safety considerations. Dietary fiber eligibility screening worked well at target values. These differences were not predicted by reliability/validity studies.


Subject(s)
Colonic Neoplasms/prevention & control , Diet Records , Feeding Behavior , Nutrition Surveys , Adult , Aged , Aged, 80 and over , Arizona , Calcium, Dietary/administration & dosage , Cohort Studies , Colonic Neoplasms/etiology , Colonic Polyps/etiology , Colonic Polyps/prevention & control , Dietary Fiber/administration & dosage , Eligibility Determination , Female , Humans , Male , Mass Screening , Middle Aged , Neoplasm Recurrence, Local/etiology , Neoplasm Recurrence, Local/prevention & control , Patient Selection , Reproducibility of Results , Risk
17.
Biopharm Drug Dispos ; 18(3): 259-69, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9113347

ABSTRACT

A comparative pharmacokinetic trial was performed with a superpotent synthetic melanotropic peptide, [Nle4-D-Phe7]-alpha-MSHi-13 (melanotan-I or MT-I) given by three routes of administration. Plasma levels were measured by RIA and tanning was quantiated using serial reflectometry. Doses of 0.16 mgkg-1 were administered intravenously (IV) and orally (PO), and doses from 0.08 to 0.21 mg kg-1 subcutaneously (SC), in a randomized crossover fashion to three male volunteers over five consecutive days for 2 weeks (ten doses). The results indicate that the SC dose is completely bioavailable compared to the IV dose. No detectable drug levels were observed following PO dosing. The plasma half-lives following SC dosing ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the beta-phase. Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and 3.9% or less of the dose was recovered in the urine. Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing. Significant tanning of the forehead, arms, and neck was noted following IV or SC dosing. This effect peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen. It is concluded that SC administration is an efficacious method of delivering melanotan-I.


Subject(s)
Anticarcinogenic Agents/pharmacokinetics , Skin Pigmentation/drug effects , alpha-MSH/analogs & derivatives , Administration, Oral , Adult , Anticarcinogenic Agents/administration & dosage , Anticarcinogenic Agents/blood , Anticarcinogenic Agents/pharmacology , Biological Availability , Cross-Over Studies , Dose-Response Relationship, Drug , Half-Life , Humans , Injections, Intravenous , Injections, Subcutaneous , Male , Radioimmunoassay , White People , alpha-MSH/administration & dosage , alpha-MSH/blood , alpha-MSH/pharmacokinetics , alpha-MSH/pharmacology
18.
Am J Prev Med ; 13(2): 98-103, 1997.
Article in English | MEDLINE | ID: mdl-9088445

ABSTRACT

INTRODUCTION: Our objective was to investigate the relationship of vaccine or toxoid licensure with the incidence of the target disease in the United States. METHODS: We used a historical correlational study design with outcome measures of the national incidence and elimination rate of polio, pertussis, diphtheria, and measles as well as the New York City incidence and elimination rate of mumps, rubella, and tetanus. RESULTS: The licensure of pertussis, measles, polio, mumps, and rubella vaccine was followed by an increase in the elimination rate of disease. The elimination rates of diphtheria and tetanus apparently worsened following the licensure of the respective toxoids. CONCLUSIONS: Historical data provide evidence of proof of efficacy of mass immunization for measles, polio, rubella, mumps, and pertussis, but not for diphtheria or tetanus.


Subject(s)
Communicable Disease Control/history , Communicable Diseases/epidemiology , Immunization Programs/history , Communicable Diseases/history , Drug Approval/history , History, 20th Century , Humans , Incidence , New York City/epidemiology , Program Evaluation , Regression Analysis , United States/epidemiology , Vaccines/history
19.
Cancer Epidemiol Biomarkers Prev ; 6(3): 161-9, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9138658

ABSTRACT

Colorectal cancers continue as the second most common cause of death from cancer in the United States. Only a few prospective, randomized clinical trials have been performed to evaluate the potential preventive effects of dietary fiber or calcium in patients with an increased risk for the development or recurrence of colorectal cancer. We designed and conducted a double-blinded, placebo-controlled randomized trial involving supplementation of fiber and calcium intake and measurements of [3H]thymidine labeling index (LI) percentages in rectal mucosal biopsies obtained from patients with resected colorectal adenomas to examine the potential mechanisms by which dietary interventions might reduce colorectal cancer risk. We performed a randomized, double-blinded, Phase II study, using a factorial design to measure the effects of supplemental dietary wheat bran fiber (2.0 or 13.5 g/day) and calcium carbonate (250 or 1500 mg/day elemental calcium) supplementation on [3H]thymidine LI percentages in rectal mucosal crypts and 24-h in vitro outgrowth cultures. Measurements were made at baseline randomization (i.e., after a 3-month placebo run-in period using 2.0 g of wheat bran fiber plus 250 mg of calcium carbonate) and after 3 and 9 months on treatment in 100 randomized participants who had a history of colon adenoma resection. Neither the wheat bran fiber nor the calcium carbonate supplements significantly reduced [3H]thymidine LI percentages in rectal mucosal crypts (total or compartmental analysis) or 24-h in vitro outgrowth cultures at either 3 or 9 months of daily supplementation in the 93 evaluable participants. We conclude that 9 months of high-dose wheat bran fiber and calcium carbonate supplementation in study participants with a history of recently resected colorectal adenomas does not have a significant effect on cellular proliferation rates in rectal mucosal biopsies, comparing 3- and 9-month results to baseline results. Ultimately, there is great need for the evaluation of these two different nutrient interventions in the setting of Phase III studies wherein adenomatous polyp recurrence, rather than a rectal mucosal biomarker, serves as the primary end point.


Subject(s)
Adenomatous Polyps/surgery , Calcium Carbonate/therapeutic use , Calcium, Dietary/therapeutic use , Colonic Polyps/surgery , Dietary Fiber/therapeutic use , Intestinal Mucosa/pathology , Rectal Neoplasms/surgery , Rectum/pathology , Adenomatous Polyps/pathology , Adenomatous Polyps/prevention & control , Aged , Calcium Carbonate/administration & dosage , Calcium, Dietary/administration & dosage , Cell Division/drug effects , Cells, Cultured , Colonic Polyps/pathology , Colonic Polyps/prevention & control , Dietary Fiber/administration & dosage , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Placebos , Prospective Studies , Rectal Neoplasms/pathology , Rectal Neoplasms/prevention & control , Risk Factors , Thymidine , Tritium
20.
Exp Clin Psychopharmacol ; 5(1): 54-64, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9234040

ABSTRACT

The effects of using several nicotine replacement treatments on self-reported withdrawal symptoms and side effects during 2-day periods of smoking cessation, with 5 days of ad lib smoking between cessation days, were evaluated. Participants (N = 18) experienced the following conditions: nicotine gum, 24-hr patch, 16-hr patch, 24-hr patch plus gum, double 24-hr patch, and no nicotine replacement. The present study found morning urge to smoke was greater during the 16-hr than during the 24-hr patch condition. Double-patch use resulted in significantly greater insomnia than the smoking baseline and 16-hr patch conditions. The no medication and gum alone conditions resulted in similar withdrawal symptoms, and both tended to result in greater reported withdrawal symptoms than the smoking baseline condition. There were no significant withdrawal symptom differences between the 24-hr, patch-gum, and double-patch conditions. The 24-hr and double-patch conditions were preferred by two thirds of the participants (6 each).


Subject(s)
Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Smoking Cessation/psychology , Substance Withdrawal Syndrome/psychology , Administration, Cutaneous , Adult , Affect/drug effects , Blood Pressure/drug effects , Carbon Monoxide/blood , Central Nervous System Stimulants/therapeutic use , Chewing Gum , Dose-Response Relationship, Drug , Female , Humans , Male , Nicotine/administration & dosage , Nicotine/analogs & derivatives , Nicotine/pharmacokinetics , Nicotine/therapeutic use , Nicotinic Agonists/administration & dosage , Nicotinic Agonists/pharmacokinetics , Polymethacrylic Acids/therapeutic use , Polyvinyls/therapeutic use , Saliva/metabolism , Tobacco Use Cessation Devices
SELECTION OF CITATIONS
SEARCH DETAIL
...